Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,824.12
    +1,734.06 (+2.51%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +42.10 (+1.90%)
     
  • Crude Oil

    83.11
    +1.76 (+2.16%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Drugmaker Boehringer offers EU concessions for Sanofi asset swap

BRUSSELS - German drugmaker Boehringer Ingelheim has offered concessions in an attempt to win EU antitrust approval for its $20 billion asset swap with France's Sanofi (SASY.PA), which would make it the second-largest company in the global animal health market.

Notice of the offer was published on the European Commission's website on Friday without providing details.

The EU executive delayed its decision on the merger to July 28 from July 13 to seek feedback from third parties before deciding whether to accept the proposal.

The swap deal would give Boehringer Sanofi's Merial animal health unit -- which has an enterprise value of 11.4 billion euros ($12.6 billion) -- in return for its consumer health arm.

ADVERTISEMENT

Sanofi's acquisition of the consumer health operations is being scrutinised separately by the EU competition watchdog, with a decision scheduled for July 20.

(Reporting by Foo Yun Chee; Editing by David Goodman)